Abstract:Leukocyte immunoglobulin (Ig)-like receptors (LILRs), also known as CD85 and immunoglobulin-like transcripts (ILTs), play pivotal roles in regulating immune responses. These receptors define an immune checkpoint that immune therapy can target. Through cis or trans interactions with human leukocyte antigen (HLA)-G, the two most abundantly expressed inhibitory LILRs, LILRB1, and LILRB2 (LILRB1/2, also known as CD85j/d and ILT2/4), are involved in immunotolerance in pregnancy and transplantation, autoimmune diseases, and immune evasion by tumors. Although the discrete domains of LILRB1/2 are clear, the assembly mode of the four extracellular Ig-like domains (D1, D2, D3, and D4) remains unknown. Previous data indicate that D1D2 is responsible for binding to HLA class I (HLA-I), but the roles of D3D4 are still unclear. Here, we determined the crystal structure of the four Ig-like domain LILRB2 and four-domain LILRB1 in complex with HLA-G1. The angles between adjacent domains and the staggered assembly of the four domains suggest limited flexibility and limited plasticity of the receptors during ligand binding. The complex structure of four-domain LILRB1 and HLA-G1 supports the model that D1D2 is responsible for HLA-I binding, while D3D4 acts as a scaffold. Accordingly, cis and trans binding models for HLA-I binding to LILRB1/2 are proposed. The geometries of LILRB1/2 in complex with dimeric and monomeric HLA-G1 suggest the accessibility of the dimeric receptor, which in turn, transduces more inhibitory signals. The assembly of LILRB1/2 and its binding to HLA-G1 could aid in the design of immune regulators and benefit immune interference.

Crystal structure of the human LAG-3–HLA-DR1–peptide complex

Structural basis for mouse LAG3 interactions with the MHC class II molecule I-Ab

Cutting Edge: LAG3 Dimerization Is Required for TCR/CD3 Interaction and Inhibition of Antitumor Immunity

The immune checkpoint receptor LAG3: Structure, function, and target for cancer immunotherapy

The ligand-dependent suppression of TCR signaling by the immune checkpoint receptor LAG3 depends on the cytoplasmic RRFSALE motif

Impact of HLA-DR Antigen Binding Cleft Rigidity on T Cell Recognition

The Crystal Structure of a T Cell Receptor in Complex with Peptide and MHC Class II

LAG3 associates with TCR–CD3 complexes and suppresses signaling by driving co-receptor–Lck dissociation

Understanding LAG-3 Signaling

The Crystal Structure of a TL/CD8αα Complex at 2.1 Å Resolution: Implications for Modulation of T Cell Activation and Memory

Crystal structure of a complete ternary complex of T-cell receptor, peptide–MHC, and CD4

CD3/TCR Complex-Associated Lymphocyte Activation Gene-3 Molecules Inhibit CD3/TCR Signaling

Structures of the four Ig-like domain LILRB2 and the four-domain LILRB1 and HLA-G1 complex

The Structural Basis for Recognition of Human Leukocyte Antigen Class I Molecules by the Pan-HLA Antibody W6/32

Dissociation of LAG-3 inhibitory cluster from TCR microcluster by immune checkpoint blockade

Crystal Structure of Vδ1 T Cell Receptor in Complex with CD1d-Sulfatide Shows MHC-like Recognition of a Self-Lipid by Human Γδ T Cells

LAG3 (CD223) and Autoimmunity: Emerging Evidence.

Design and Biophysical Characterization of Second-Generation Cyclic Peptide LAG-3 Inhibitors for Cancer Immunotherapy

Structure and function of a potent agonist for the semi-invariant natural killer T cell receptor.

CD94-NKG2A recognition of human leukocyte antigen (HLA)-E bound to an HLA class I leader sequence

Crystal Structure Of The Human Cd4 N-Terminal Two-Domain Fragment Complexed To A Class Ii Mhc Molecule